Engineered immune cells take on hard-to-treat lymphoma

NCT ID NCT07288879

Recruiting now Disease control Sponsor: Miltenyi Biomedicine GmbH Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated Jun 16, 2026 · Updated 30 times

Summary

This study tests a new treatment called zamtocabtagene autoleucel (MB-CART2019.1) for people with diffuse large B cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, which are genetically modified to recognize and attack lymphoma cells. The main goal is to see how many patients' tumors shrink or disappear after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Juntendo University Hospital
NOT_YET_RECRUITING

Tokyo, 113-8431, Japan
Keio University Hospital
NOT_YET_RECRUITING

Tokyo, 160-8582, Japan
National Cancer Center Hospital
RECRUITING

Tokyo, 104-0045, Japan
Tokyo Metropolitan Komagome Hospital
RECRUITING

Tokyo, 113-8677, Japan
Toranomon Hospital
NOT_YET_RECRUITING

Tokyo, 105-8470, Japan

Conditions

Explore the condition pages connected to this study.

CAR T CELL THERAPY CAR T CELL THERAPY CAR-T CELL THERAPY DLBCL - DIFFUSE LARGE B CELL LYMPHOMA